scholarly journals Introduction of new tumor marker age score in clinical practice: Validity evaluation for differentiation benign from malignant adnexal masses

2012 ◽  
Vol 59 (3) ◽  
pp. 49-56
Author(s):  
Ivana Likic-Ladjevic ◽  
Milan Terzic ◽  
Nebojsa Ladjevic ◽  
Jelena Dotlic ◽  
Igor Pilic ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Tumor Marker ◽  
Tumor Markers ◽  
Ca 125 ◽  
Benign Tumors ◽  
Tumor Type ◽  
Adnexal Masses ◽  
Combined Tumor ◽  
Adnexal Tumor ◽  
Adnexal Tumors

OBJECTIVE: The aim of the study was to examine several tumor markers and their correlation with pathohistological findings in patients with adnexal masses. METHODS: Study involved 139 patients, 84 of them with benign, 47 with malignant and 8 with borderline adnexal tumor. Levels of CA 125, CA 19-9, CEA and CA 15-3 were obtained preoperatively and assessed regarding the specific pathohistological diagnose and the patient?s age. Obtaining these results led us to divide the patient?s CA 125 levels with age and by doing that we have attained a new Tumor Marker Age score (TMA score). Results: Patients with malignant adnexal tumors had significantly higher levels of CEA (p<0.05), CA 125, CA 19-9 and CA 15-3 tumor markers (p<0.01), in comparison with patients with benign tumors. TMA score highly statistically correlate with the tumor type (benignant/malignant). CONCLUSIONS: With the increase of tumor marker levels and the patient?s age the malignant nature of adnexal tumors is more often. Results of our study highlight the importance of the use of combined tumor markers (at least CA-125 and CA 19-9) in women with adnexal masses. Those levels along with the patient?s age and new TMA score could preoperatively predict malignant nature of the tumor.

scholarly journals Circulating markers of neutrophil extracellular traps (NETs) in patients with ovarian tumors

2021 ◽  
Author(s):  
Arturas Dobilas ◽  
Charlotte Thålin ◽  
Håkan Wallén ◽  
Christer Borgfeldt
Keyword(s):  
Ovarian Cancer ◽  
Plasma Levels ◽  
Neutrophil Extracellular Traps ◽  
Ovarian Tumors ◽  
Ca 125 ◽  
Benign Tumors ◽  
Tumor Type ◽  
Cox Regression Analysis ◽  
Adnexal Masses ◽  
Extracellular Traps

Abstract Background Inflammation is a hallmark of cancer, and emerging light is being shed on the neutrophil release of nuclear chromatin, referred to as neutrophil extracellular traps (NETs) in cancer and cancer associated thrombosis. The NET-specific marker citrullinated histone H3 (H3Cit) has been found to be elevated in plasma from patients with malignancies, suggesting the potential of NET markers, such as H3Cit, as novel cancer biomarkers. Objective To determine the levels of plasma H3Cit in blood in women with adnexal masses. Subjects and Method s: Peripheral blood samples were obtained preoperatively from 199 patients admitted for primary surgery of adnexal masses 2015–2017. Patients were grouped according to tumor type and stage of cancer. Plasma levels of H3Cit-DNA, cell free DNA (cfDNA) and the clinically implemented tumor marker cancer antigen 125 (CA125) were determined with ELISA. Results Plasma levels of H3Cit-DNA and cfDNA were not elevated in women with borderline or malignant ovarian tumors compared with women with benign tumors. Increased plasma levels of CA125 were detected in borderline and ovarian cancer stage I and stage II-IV compared with benign ovarian tumor patients (ptrend<0.001). In Cox regression analysis high levels of Ca 125 dichotomized at 326 IU/ml (median) showed worse overall survival hazard ratio 1.9 (95 % C.I. 1.03–3.36; p = 0.038). No differences were found in the survival analyses in malignant ovarian tumors analyzing the cfDNA and H3Cit-DNA levels. Conclusion This study did not find any association nor prognostic association between the plasma levels of the NET marker H3Cit and ovarian cancer patients.

scholarly journals Tumor marker CA-125 in adnexal inflammatory tumors

2006 ◽  
Vol 63 (4) ◽  
pp. 383-385
Author(s):  
Branka Nikolic ◽  
Daniela Ardalic ◽  
Jelena Lazic
Keyword(s):  
Tumor Marker ◽  
Doppler Ultrasonography ◽  
Combined Therapy ◽  
Resistance Index ◽  
Ca 125 ◽  
Pelvic Cavity ◽  
Malignant Diseases ◽  
Specific Tumor ◽  
Adnexal Tumor ◽  
Adnexal Tumors

Background/Aim. The glycoprotein of a high molecular weight CA-125, which is not a specific tumor marker of ovarian cancer, is secreted by the endothelial cells of most pelvic organs. Endometriosis, inflammatory processes in the pelvic cavity, as well as some nongynecoligical malignant diseases, could be followed by the increased values of CA-125. Serial assessment of the values of CA- 125 makes it possible to avoid surgical treatment, and, by means of the used conservative treatment, to avoid malignant diseases not to be noticed. Methods. The study included 57 female patients hospitalized due to inflammable adnexal tumors. Besides following the values of serum CA-125 during and after the therapy, also performed were the transvaginal Doppler ultrasonography and the determination of the values of resistance index (RI). Results. In 27 patients (55.1%) the CA-125 values ranged from 38.8 U/ml to 794 U/ml, while in 30 of the patients they were within the range of normal. In this group of the patients, besides the increased values of CA- 125, also increased were the values of leucocytes (119/l ? 209/l), as well as the sedimentation rates (65?120) within the first hour. In all the 57 patients, transvaginal Doppler ultrasonography revealed the presence of adnexal tumor of inflammatory kind. The measured values of RI were within the range of 0.539?0.681. Eight of the patients were treated by the conservative - triple antibiotic therapy, while in 49 patients explorative laparotomy was performed. Hystorectomy was done in 12 of the patients, and one-side adnexectomy in 37 of them. Conclusion. The method for the assessment of CA-125 is simple and available which facilitates the monitoring of surgical, conservative or the combined therapy that is particularly significant in younger patients with inflammable adnexal tumor developed on the basis of endometrosis.

Risk of Metastatic Ovarian Involvement in Nongynecologic Malignancies

2012 ◽  
Vol 22 (1) ◽  
pp. 3-8 ◽  
Author(s):  
Kidong Kim ◽  
Soo Youn Cho ◽  
Sang-Il Park ◽  
Hye Jin Kang ◽  
Beob-Jong Kim ◽  
...  
Keyword(s):  
Overall Survival ◽  
Malignant Tumors ◽  
Rank Test ◽  
Benign Tumors ◽  
Binary Logistic Regression Analysis ◽  
Fisher Exact Test ◽  
Tumor Type ◽  
Metastatic Tumors ◽  
Number Of Patients ◽  
Adnexal Tumors

ObjectiveThe objectives were to evaluate the risk of malignant adnexal tumors in women with nongynecologic malignancies and to identify variables associated with the risk of malignant adnexal tumors.MethodsThe eligibility criteria included the diagnosis of a nongynecologic malignancy and adnexal tumors, which were resected or subjected to biopsy at our institute between 1999 and 2010. The risk of malignant adnexal tumors was assessed by dividing the number of patients with metastatic tumors to the adnexa or primary adnexal cancers by the total number of patients. The association of clinicopathologic variables with the risk of malignant adnexal tumors was evaluated using the Fisher exact test and binary logistic regression analysis. In patients with metastatic tumors to the adnexa, the association of clinicopathologic variables with overall survival after adnexal surgery was examined using the log-rank test.ResultsIn 166 patients with adnexal tumors, 41 benign tumors, 113 metastatic tumors to the adnexa, and 12 primary adnexal cancers were diagnosed. Age older than 46 years, a tumor type associated with a high risk for malignant adnexal tumors, and bilateral tumors significantly increased the risk of malignant adnexal tumors. The overall survival of the patients with stomach cancer was significantly worse than the patients with colorectal or breast cancers.ConclusionOne hundred twenty-five of the 166 patients with nongynecologic malignancies who had adnexal tumors managed surgically were shown to have malignant tumors, and most of the tumors were metastatic from primary sites. The risk of malignant adnexal tumors was associated with age, nongynecologic malignancy, and bilaterality.

scholarly journals SERUM TUMOR MARKERS

2006 ◽  
Vol 13 (01) ◽  
pp. 1-10
Author(s):  
FAISAL BILAL LODHI ◽  
DR IFTIKHAR ◽  
MUHAMMAD ALI ◽  
Riaz Hussain
Keyword(s):  
Tumor Marker ◽  
Tumor Markers ◽  
Specific Antigen ◽  
Germ Cell Tumors ◽  
Metastatic Breast ◽  
Chemotherapeutic Agents ◽  
Response To Therapy ◽  
Ca 125 ◽  
Care Practice ◽  
Monitoring Response

With the advent of new generations of chemotherapeutic agents andadvances in radiation therapy in the management of malignancies, an understanding of tumor markers is becomingincreasingly important. These soluble molecules in the blood are usually glycoproteins detected by monoclonalantibodies. Each tumor marker has a variable profile of usefulness for screening, determining diagnosis and prognosis,assessing response to therapy, and monitoring for cancer recurrence. Monoclonal antibodies are used to detect serumantigens associated with specific malignancies. These tumor markers are most useful for monitoring response totherapy and detecting early relapse. With the exception of Prostate-Specific Antigen (PSA), tumor markers do not havesufficient sensitivity or specificity for use in screening. Cancer Antigen (CA) 27.29 most frequently is used to followresponse to therapy in patients with metastatic breast cancer. Carcinoembryonic antigen is used to detect relapse ofcolorectal cancer, and CA 19-9 may be helpful in establishing the nature of pancreatic masses. CA 125 is useful forevaluating pelvic masses in postmenopausal women, monitoring response to therapy in women with ovarian cancer,and detecting recurrence of this malignancy. Alpha-fetoprotein (AFP), a marker for hepatocellular carcinoma,sometimes is used to screen highly selected populations and to assess hepatic masses in patients at particular riskfor developing hepatic malignancy. Testing for the beta subunit of human chorionic gonadotropin (b-hCG) is an integralpart of the diagnosis and management of gestational trophoblastic disease. Combined AFP and b-hCG testing is anessential adjunct in the evaluation and treatment of nonseminomatous germ cell tumors, and in monitoring theresponse to therapy. AFP and b-hCG also may be useful in evaluating potential origins of poorly differentiatedmetastatic cancer. PSA is used to screen for prostate cancer, detect recurrence of the malignancy, and evaluatespecific syndromes of adenocarcinoma of unknown primary. This review article describes the use of common tumormarkers in primary care practice. Particular emphasis is given to when these tests should be ordered and to commonfactors that influence the interpretation of tumor marker levels.

Clinical ambiguousness of measurement of tumor markers in the differential diagnosis of the uterus appendages tumors and inflam-matory pelvic mass in girls

2015 ◽  
Vol 6 (1) ◽  
pp. 115-119
Author(s):  
Nadezda Anatolyevna Kokhreidze ◽  
Svetlana Alekseevna Leontyeva
Keyword(s):  
Differential Diagnosis ◽  
Tumor Marker ◽  
Tumor Markers ◽  
Acute Phase Proteins ◽  
Pelvic Mass ◽  
Ca 125 ◽  
Childhood And Adolescence ◽  
Direct Proportion ◽  
Marker Test ◽  
Tumor Specificity

In the diagnosis of ovarian tumors, with the most frequent gystotypes specific to childhood and adolescence, is widely used of tumor markers tests: alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG) and Ca-125. Features of the development of malignancies in children restrict of tumor markers tests in clinical practice. At the same time there are no tumor marker with 100 % specificity for the tumor. The article describes the clinical cases of 13-year-old female patient with appendicular infiltrate and secondary right adnekstumor and 14-year-old girl with hematogenous disseminated tuberculosis and salpingooophorities. The levels of Ca-125 and was an increased in both cases: in the first - to 39.41 IU/ml, in the second - up to 928.1 IU/ml. Thus, it was confirmed that the increase of serum concentration of CA-125 were in direct proportion to the pathological “irritation” of peritoneal serosa. In fact, the Ca-125 had the feature of acute phase proteins, so, its tumor specificity was low. Therefore the use of tumor marker test for Ca-125 is not always makes more easy task of differential diagnosis of the nature of the tumor mass pelvic in girls.

scholarly journals Mass lesions of ovary - Tumor markers can be misleading

2014 ◽  
Vol 6 (3) ◽  
pp. 26-29
Author(s):  
Moothiringode Chitrabhanu Savithri ◽  
Usha Mary Abraham
Keyword(s):  
Tumor Marker ◽  
Tumor Markers ◽  
Ovarian Tumors ◽  
Treatment Modalities ◽  
Ca 125 ◽  
Medical Sciences ◽  
Ovarian Carcinomas ◽  
Ovary Tumor ◽  
Mass Lesions ◽  
Sex Cord Stromal Tumors

Background: Ovarian mass lesions could be neoplastic or non neoplastic. The less aggressive lesions should be distinguished from carcinomas which require extensive surgical procedures. CA-125 is a tumor marker used for evaluating ovarian carcinomas. In this series we found seven cases of sex cord stromal tumors (SCT) and endometriotic cysts with raised CA-125 levels, the highest value being 1540 IU/ml. Aims and Objectives: 1) To retrospectively evaluate cases which presented as mass lesions of ovary over a two year period along with CA-125 levels if available. 2) To find out the number of non carcinomatous lesions with elevation of the tumor marker CA-125. Materials and Methods: Total number of ovarian tumors and endometriotic cysts reported in the Department of Pathology, Amala Institute of Medical Sciences, Thrissur, Kerala, India in the two year period of 2012 and 2013 were retrospectively identified. CA-125 levels if available were noted. Results: Primary ovarian tumors comprised 180 cases, the rest being metastastic adenocarcinomas. There were 15 cases of SCT and 21 endometriotic cysts. CA 125 levels were increased in 2 cases each of granulosa cell tumors and fibrothecomas and 3 cases of endometriotic cysts. Highest value was 1540 IU/ml. Conclusion: Elevation of the tumor marker CA 125 often tricks the clinician into making a provisional diagnosis of carcinoma of ovary. It is important to understand the limitations in the interpretation of tumor markers so that more aggressive treatment modalities are avoided. DOI: http://dx.doi.org/10.3126/ajms.v6i3.10983  Asian Journal of Medical Sciences Vol.6(3) 2015 26-29 

scholarly journals Parameters of Blood Count and Tumor Markers in Patients with Borderline Ovarian Tumors: A Retrospective Analysis and Relation to Staging

ISRN Oncology ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Rosekeila Simões Nomelini ◽  
Taísa Morete da Silva ◽  
Beatriz Martins Tavares Murta ◽  
Eddie Fernando Candido Murta
Keyword(s):  
Tumor Markers ◽  
Blood Count ◽  
Ovarian Tumors ◽  
Ca 125 ◽  
Borderline Ovarian Tumor ◽  
Tumor Type ◽  
Borderline Ovarian Tumors ◽  
Stage Ib ◽  
Ca 19.9 ◽  
Stage Ia

The aim of this paper was to evaluate the parameters of blood count and tumor markers in borderline ovarian tumors. We evaluated 21 patients who had confirmed histopathologic diagnosis of borderline ovarian tumor. We recorded age, parity, tumor type, stage of cancer, serum levels of tumor markers (CA-125, CA-15.3, CA-19.9, CEA, AFP), and the parameters of blood count, fasting glucose, disease-free survival and overall. The patients were divided into two groups, stage IA (n=13) and stage IB-IIIC (n=8). The unpaired t-test and Fisher's exact test were used, with P values of less than 0.05 being considered to indicate statistical significance. Levels of red blood cells, hematocrit, and hemoglobin were significantly higher in stage IA when compared with stage IB-IIIC (P<0.05). The levels of tumor marker CEA had a tendency to be higher in the group stage IB-IIIC (0.08). Abnormal levels of CEA and CA-19.9 were found more frequently in stages IB-IIIC. Therefore, parameters of blood count, CEA, and CA-19.9 should be targeted for further research in identifying prognostic factors in borderline tumors.

Comparison of CA 125 and Placental Alkaline Phosphatase as Ovarian Tumor Markers

1987 ◽  
Vol 73 (3) ◽  
pp. 301-302 ◽  
Author(s):  
Pentti K. Heinonen ◽  
Olli-Pekka Kallioniemi ◽  
Timo Koivula
Keyword(s):  
Ovarian Cancer ◽  
Alkaline Phosphatase ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Ovarian Tumor ◽  
Serum Levels ◽  
Ca 125 ◽  
Placental Alkaline Phosphatase ◽  
Serum Concentrations

The serum concentrations of CA 125 and placental alkaline phosphatase were analyzed in 16 patients with ovarian cancer. Increased serum levels of CA 125 and placental alkaline phosphatase were observed in 75% and 50% of the cancer patients, respectively. The serum levels of these tumor markers were not correlated, supporting their distinct antigenic nature. CA 125 seems to be a more promising tumor marker for ovarian cancer than placental alkaline phosphatase.

scholarly journals Which Parameters could be Useful for Predicting Malignancy in Solid Adnexal Masses?

2009 ◽  
Vol 3 (1) ◽  
pp. 1-5
Author(s):  
Juan Luis Alcázar ◽  
Pedro Royo ◽  
Laura Pineda
Keyword(s):  
Blood Flow ◽  
Logistic Regression ◽  
Regression Analysis ◽  
Logistic Regression Analysis ◽  
Malignant Tumors ◽  
Univariate Analysis ◽  
Menopausal Status ◽  
Ca 125 ◽  
Benign Tumors ◽  
Adnexal Masses

Abstract To determine which clinical, biochemical and other sonographic parameters could be useful to predict malignancy in sonographically solid adnexal masses. Methods Clinical (age, menopausal status, complaints and physical examination), biochemical (serum CA-125 levels) and other sonographic features (tumor volume, ascites, bilaterality, blood flow location and velocimetric pattern) from 163 women diagnosed as having a solid adnexal mass on B-mode gray-scale ultrasound were reviewed for this retrospective study. All patients had undergone surgery and mass removal. Definitive histologic diagnosis was available in all cases. All parameters were compared to final histological diagnosis (benign or malignant) in univariate statistical analysis. Then a stepwise forward logistic regression analysis was performed to identify those features that independently predict malignancy. Results A total of 173 masses were analyzed. Patients mean age was 52.4 years (range: 15 to 84 years) 117 masses were malignant and 56 were benign. After univariate analysis all parameters showed statistical differences between benign and malignant tumors. After logistic regression analysis only central blood flow (odd ratio: 64.2, 95% CI: 17.07 to 242.03) and presence of ascites (odd ratio: 32.77, 95% CI: 5.38 to 199.72) were identified as independent predictors of malignancy. The presence of one of these two features correlated to malignancy in 98.6% of cases. The absence of both was found in 82.1% of benign tumors. Conclusions The presence or absence of ascites or central blood flow may be helpful for discriminating benign from malignant solid adnexal masses.

scholarly journals Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers

Tumor Biology ◽  
2017 ◽  
Vol 39 (10) ◽  
pp. 101042831773024 ◽  
Author(s):  
Ramona C Dolscheid-Pommerich ◽  
Mignon Keyver-Paik ◽  
Thomas Hecking ◽  
Walther Kuhn ◽  
Gunther Hartmann ◽  
...  
Keyword(s):  
Tumor Marker ◽  
Tumor Markers ◽  
Clinical Performance ◽  
Ca 125 ◽  
Gynecological Cancers
Sign in / Sign up

Export Citation Format

Share Document